Multi-drug resistance (MDR) is one of the obstacles for leukemia therapy, the major cause is
an overexpression of P-glycoprotein (P-gp) leading to increased drug efflux. We investigated …

Introduction: To study the effect of bortezomib alone or in combination with daunorubicin
(DNR) on an mdr1 single‐factor drug‐resistant leukemia cell line K562/MDR1, a multifactor …

Purpose The proteasome inhibitor bortezomib may be effective in combination with
cytarabine and anthracyclines in the treatment of acute myeloid leukemia (AML) by virtue of …

Multidrug resistance (MDR) of tumor cells has become the main impediment that influence
the curative effect of cancer chemotherapy. Although there are many mechanisms can …

Multidrug resistance (MDR) in cancer is a major problem in clinical settings: MDR correlates
with a patient's poor prognosis and decreased quality of life. Recently, MDR was found to be …

Multidrug resistance is a serious obstacle encountered in leukemia treatment. Previous
studies have found drug resistance in human leukemia is mainly associated with …

This study was purposed to investigate whether the mdr1 participates in antiapoptotic
mechanisms of hematologic malignant cells regulated by NF-kappaB and to explore the …

P-glycoprotein (P-gp) is the plasma membrane transport pump responsible for efflux of
chemotherapeutic agents from cells and is one of the systems that secures multidrug …

Methods A human leukemic cell line K562/A02 was established by stepwise increase of
concentrations of doxorubicin (Dox) in medium. P-glycoprotein was detected by …

Numerous signaling pathways were reported to be involved in the resistance for
conventional cytotoxic drugs, although one of the main reasons is the overexpression of P …